Head, Neck and CNS Malignancies

Friday, May 4, 2018 from 7:30 AM to 8:30 AM
Available for up to 1.00 hours of CPE credit
Activity Number: 0217-9999-18-080-L01-P

Christine M. Walko, Pharm.D., BCOP

  • Faculty: Christine M. Walko, Pharm.D., BCOP
    Clinical Pharmacogenetics Scientist, Moffitt Cancer Center, Tampa, Florida
      View Biography

Learning Objectives
1. Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, or adult central nervous system (CNS) cancer.
2. Assess relevant pharmacogenomic considerations related to anticancer agents used to treat head, neck, or CNS cancer.
3. Select relevant information and provide guidance to the public regarding head and neck -related issues (e.g., risk factors, prevention, screening).
4. Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cachexia, mucositis, and xerostomia.
© 2019 American College of Clinical Pharmacy and American Society of Health‑System Pharmacists